309
Participants
Start Date
August 31, 2009
Primary Completion Date
November 30, 2010
Study Completion Date
October 31, 2015
Ruxolitinib
Ruxolitinib phosphate tablets 5 mg administered as oral doses.
Placebo
Matching placebo tablets were administered as oral doses in the same manner as active drug.
Birmingham
Scottsdale
Baldwin Park
Bellflower
Beverly Hills
Corona
Fullerton
Highland
La Jolla
Los Angeles
Orange
Palo Alto
Panorama City
Rancho Cucamonga
Riverside
Sacramento
San Diego
West Covina
Aurora
Denver
Fort Collins
Norwalk
Washington D.C.
Boynton Beach
Gainesville
Jacksonville
West Palm Beach
Winter Park
Atlanta
Augusta
Honolulu
Boise
Meridian
Twin Falls
Chicago
Beech Grove
Indianapolis
Ames
Iowa City
Sioux City
Waterloo
Louisville
Alexandria
New Orleans
Baltimore
Ann Arbor
Detroit
Novi
Southfield
Minneapolis
Rochester
Saint Louis Park
New Albany
St Louis
Billings
Denville
Hackensack
Morristown
Somerville
Albuquerque
East Setauket
New York
Valhalla
Durham
Hickory
Winston-Salem
Bismarck
Akron
Canton
Cleveland
Dayton
Dover
Portland
Philadelphia
Pittsburgh
Charleston
Germantown
Memphis
Nashville
Dallas
Houston
New Braunfels
San Antonio
Salt Lake City
Burlington
Everett
Seattle
Milwaukee
Darlinghurst
Kogarah
Randwick
St Leonards
Brisbane
Douglas
Herston
Milton
Woolloongabba
Bedford Park
Box Hill
Clayton
Frankston
Ringwood East
Fremantle
Perth
Vancouver
St. John's
Halifax
London
Ottawa
Toronto
Lévis
Montreal
Lead Sponsor
Incyte Corporation
INDUSTRY